<SEC-DOCUMENT>0001558370-21-011566.txt : 20210813
<SEC-HEADER>0001558370-21-011566.hdr.sgml : 20210813
<ACCEPTANCE-DATETIME>20210813070522
ACCESSION NUMBER:		0001558370-21-011566
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210812
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210813
DATE AS OF CHANGE:		20210813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		211169693

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20210812x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7811.37134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/13/2021 11:05:04 AM -->
      <!-- iXBRL Library version: 1.0.7811.37150 -->
      <!-- iXBRL Service Job ID: cb2abe4f-f5a1-4a6e-b3c3-13867968190f -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20210812" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityCentralIndexKey" id="Tc_hmDQnI4EXEKQVxHjSXGb5A_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:AmendmentFlag" id="Tc_foOeh9_Dz0C-u_-xVncb-Q_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20210812.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b529d0e5_bf66_4bff_8207_e726dc50d28b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:DocumentType" id="Narr_i_H4bj5e7EKmLi068hYR0w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): August&#160;13, 2021 (</b><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_Q-hSX1_JgEuxX8LubSBLEg"><b style="font-weight:bold;">August&#160;12, 2021</b></ix:nonNumeric><b style="font-weight:bold;">)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityRegistrantName" id="Narr_N5fbASVY3UmqBnyQagWcOA"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_8sqyFgM2KU2u_yPV0apjJA_2_0"></a><a id="Tc_gRytt4xJCE6bMMVv31sAdA_2_2"></a><a id="Tc_sx3fLO3yHkWAwyJIayeuKQ_2_4"></a><a id="Tc_UebLJ-ik20GLyZhQf8WNxw_6_0"></a><a id="Tc_rlUbgWz0qk2vDALy9asBCg_7_0"></a><a id="Tc_09260-C8l0OCxZD0aueosA_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_8ANLRlDAEEazBNavx_Ve2Q_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityFileNumber" id="Tc_chCa6R_LWEGhILB-s9LiXQ_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityTaxIdentificationNumber" id="Tc_YtOjwL8cxE-xQpx4spRK3w_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer<br />Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityAddressAddressLine1" id="Tc_UGoKOL8KVE-u8azBVBYJiQ_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityAddressAddressLine2" id="Tc_Cybi8LbBn0Wi1jiAtAGrUQ_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityAddressCityOrTown" id="Narr_nb0xXsh7n0KfEsZS9tCWaQ"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityAddressStateOrProvince" id="Narr_Af7S9YQNEESYUwdyzYnI8g"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:EntityAddressPostalZipCode" id="Tc_J8QxUBbeIE-bK4Lz7srDEQ_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:CityAreaCode" id="Narr_KnMSNrGQ9kq1sj8WJaNa0Q"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:LocalPhoneNumber" id="Narr_q1OiuCxgA06eGDwfy1tZGA"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_0hkmS27GFUCCa6bowPsjNg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_62DRgwsjkEiHbKCEy5ngfA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_TEAp8lVDy0WKzcSwPBFBQg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_g8H7dux98U23Bb8h-hbUyg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_nDm801QNnESVXIQENlgBzw_1_0"></a><a id="Tc_RitLwcMWiEW028PJ6s3jxA_1_1"></a><a id="Tc_VMNTRL13r0q8Dao7Q0ITcA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:Security12bTitle" id="Tc_2eEXGvSdm0y7iYvf2NSJRQ_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" name="dei:TradingSymbol" id="Tc_hY8de9PVUEGw5mLVCzjQbw_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_ij1Mfal7T0iJS88Il81C4A_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_gRO7vsnxGE2KKMhi5ex8NA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;1.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;12, 2021, Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) entered into definitive agreements (the &#8220;Exchange Agreements&#8221;) relating to exchanges (the &#8220;Exchanges&#8221;) of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;Existing Notes&#8221;) for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;Exchange Notes&#8221;), $25.90 million in cash and accrued and unpaid interest through the cloing date. The Exchange Agreements contain customary representations, warranties and covenants by us together with customary closing conditions. The Exchanges, which will be made in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Section 4(a)(2) thereof, is expected to close as soon as practicable, subject to satisfaction of certain closing conditions. Following the closing of the Exchanges, the Company expects that $3.27&#160;million aggregate principal amount of the Existing Notes will remain outstanding. The description of the Exchange Agreements contained in this Current Report on Form&#160;8-K is qualified in its entirety by reference to the complete text of the form of the Exchange Agreement, a copy of which is filed as Exhibit 10.1 and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Exchange Notes will be issued pursuant to an Indenture to be entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent (the &#8220;Indenture&#8221;). Like the Existing Notes and at equal priority, the Exchange Notes will be secured by perfected liens on all of the material assets of the Company and its subsidiaries. Interest on the Exchange Notes will be payable semi-annually at a rate of 7.50% per annum. The Exchange Notes mature three years after issuance, unless earlier purchased, converted, exchanged or redeemed, and will be guaranteed by the Company&#8217;s subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Holders may require the Company to repurchase their Exchange Notes upon the occurrence of certain events that constitute a fundamental change under the Indenture at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Holders may convert their Exchange Notes at any time prior to the close of business on the business day immediately preceding the stated maturity date of the Exchange Notes. Upon conversion, the Company may, at its election, deliver shares of the Company&#8217;s common stock (&#8220;Common Stock&#8221;), cash or a combination of shares of Common Stock and cash based on the applicable conversion rate. However, until the Company obtains stockholder approval to issue additional shares of Common Stock upon conversion of the Exchange Notes, the Company will be required to settle at least a portion of its conversion obligation in cash. The Company intends to seek stockholder approval promptly in order to settle conversions of the Exchange Notes in Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The initial conversion rate is based on a 32.5% premium to the closing price of the Company&#8217;s Common Stock on the NYSE American at the close of trading on August&#160;13, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Indenture includes covenants customary for instruments of this type, including, without limitation, restrictions on the Company&#8217;s ability to incur additional indebtedness, create liens on its properties, pay dividends and make restricted payments or certain investments, and also requires the Company to apply a portion of the proceeds from certain asset sales or licensing arrangements to redeem the Notes, in each case subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The offer and sale of the Exchange Notes and the shares of Common Stock issuable upon conversion of the Exchange Notes, if any, will not be registered under the Securities Act or any state securities laws, and unless so registered, the Exchange Notes and such shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.03&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information set forth under Item 1.01 of this Current Report is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;3.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sale of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information set forth under Item 1.01 of this Current Report is incorporated herein by reference.</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;13, 2021, the Company issued a press release announcing the entry into the Exchange Agreements, the Exchanges and certain terms and conditions thereof. A copy of the press release is filed herewith as Exhibit&#160;99.1 and is incorporated by reference into this Current Report on Form&#160;8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</b></p><a id="a02"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="plx-20210812xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Exchange Agreement, dated as of August&#160;12, 2021 among Protalix BioTherapeutics, Inc. and the Existing Holders</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="plx-20210812xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press Release dated August&#160;13, 2021</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;13, 2021</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>plx-20210812xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/13/2021 11:04:54 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Execution Version</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="sty_hlb_0"></a><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-top:1pt;border-top:2.25pt solid #000000;margin:12pt 0pt 0pt 0pt;"><a name="sty_ht1_1"></a><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:12pt 0pt 12pt 0pt;">EXCHANGE AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hcb_2"></a>by and among</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hcb_3"></a>Protalix BioTherapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hcb_4"></a>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hcb_5"></a>the Parties Signatory Hereto</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:24pt 0pt 12pt 0pt;"><a name="sty_hcb_6"></a>Dated as of August 12, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-top:1pt;border-top:2.25pt solid #000000;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:-0pt 0pt 12pt 0pt;">EXCHANGE AGREEMENT dated as of August 12, 2021 (this &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Agreement</u>&#8221;), by and among Protalix BioTherapeutics, Inc., a Delaware corporation (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Company</u>&#8221;), and the parties signatory hereto (each, a &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Purchaser</u>,&#8221; and collectively, the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Purchasers</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:12pt 0pt 12pt 0pt;"><u style="text-decoration:underline;"><a name="sty_hcu_0"></a></u><u style="text-decoration:underline;">BACKGROUND</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of the date hereof, each Purchaser owns and holds an aggregate principal amount of the Company&#8217;s 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Existing Notes</u>&#8221;) shown opposite such Purchaser&#8217;s name under &#8220;Principal Amount of Existing Notes&#8221; on <u style="text-decoration:underline;text-decoration-color:#000000;">Schedule I</u> hereto. The Existing Notes have the covenants and terms set forth in the indenture dated as of December 7, 2016, as supplemented by the First Supplemental Indenture, dated July 24, 2017, and the Second Supplemental Indenture, dated November 27, 2017 (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Existing Indenture</u>&#8221;), between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Trustee</u>&#8221;) and Wilmington Savings Fund Society, FSB, as collateral agent (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Collateral Agent</u>&#8221;). All capitalized terms used herein that are not otherwise defined shall have the meanings ascribed to them in the Existing Indenture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Each Purchaser desires to exchange with the Company (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Exchange</u>&#8221;) its Existing Notes for (a) the aggregate principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Exchange Notes</u>&#8221;) shown opposite such Purchaser&#8217;s name under &#8220;Principal Amount of Exchange Notes&#8221; on <u style="text-decoration:underline;text-decoration-color:#000000;">Schedule I</u> hereto; (b) cash in the amount shown opposite such Purchaser&#8217;s name under &#8220;Cash Consideration&#8221; on <u style="text-decoration:underline;text-decoration-color:#000000;">Schedule I</u> hereto (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Cash Consideration</u>&#8221;) and (c) cash in the amount of the accrued and unpaid interest on such Existing Notes through, but excluding, the Closing Date (as defined below) (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Accrued Interest</u>&#8221;), in a transaction exempt from registration under the Securities Act of 1933, as amended (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Securities Act</u>&#8221;), pursuant to the provisions of Section 3(a)(9) thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Each of the Purchasers has irrevocably and unconditionally agreed to consent to the adoption of a third supplemental indenture, in form and substance reasonably acceptable to the Purchasers (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Third Supplemental Indenture</u>&#8221;) to amend the terms of the Existing Indenture to permit the issuance of the Exchange Notes, the incurrence of liens securing the Exchange Notes, the entry by the Company, the guarantors party thereto, the Trustee and the Collateral Agent into the indenture to be dated as of the Closing Date (as defined below) for the Exchange Notes (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Exchange Notes Indenture</u>&#8221;) and that the liens securing the Exchange Notes shall be pari passu with the Existing Notes and Existing Indenture (effective as of the execution of this Agreement). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In consideration of the mutual covenants and agreements contained in this Agreement, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Company and the Purchasers, severally but not jointly, hereby agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;white-space:nowrap;">Article&#160;I</font><u style="text-decoration:underline;"><a name="sty_hcu_1"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></u><u style="text-decoration:underline;">EXCHANGE</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;1.1</font><u style="text-decoration:underline;">Exchange</u><font style="line-height:1.19;">. The Company agrees to (a) issue to each Purchaser that principal amount of Exchange Notes as set forth on </font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Schedule I</u><font style="line-height:1.19;"> hereto opposite such Purchaser&#8217;s name and (b) pay to such Purchaser that amount of cash in U.S. dollars representing the sum of the Cash Consideration as set forth on </font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Schedule I</u><font style="line-height:1.19;"> hereto opposite such Purchaser&#8217;s name and the </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Accrued Interest on the Existing Notes of such Purchaser, (the consideration referenced in the foregoing clauses (a) and (b), the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Exchange Consideration</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;), in exchange for the Existing Notes of such Purchaser having the aggregate principal amount set forth on </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Schedule I</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> hereto opposite such Purchaser&#8217;s name, and each Purchaser, severally and not jointly, agrees to exchange all such Existing Notes for such Exchange Consideration.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;1.2</font><u style="text-decoration:underline;">Exchange Procedures</u><font style="line-height:1.19;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>The closing of the Exchange (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Closing</u>&#8221;) will commence upon the satisfaction or waiver of the conditions and obligations of the Company and the Purchasers to consummate the Exchange set forth in <u style="text-decoration:underline;text-decoration-color:#000000;">Article IV</u> (other than conditions and obligations with respect to the actions that the Company and the Purchasers, respectively, will take at Closing), or such other date and time as the Company and the Purchasers may mutually determine (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Closing Date</u>&#8221;); provided, however, that in the event the Closing does not occur on or prior to September 23, 2021 (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Outside Date</u>&#8221;), this Agreement shall terminate in its entirety and be of no further effect. No later than 10:00 a.m., New York City time, on the Closing Date, each Purchaser shall cause the custodian through which such Purchaser holds its Existing Notes to (i) post a DWAC request to the Trustee to effect the cancellation of the Existing Notes in accordance with the procedures of The Depository Trust Company (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">DTC</u>&#8221;), and (ii) post a DWAC request to the Trustee for free receipt of the aggregate principal amount of Exchange Notes opposite such Purchaser&#8217;s name on <u style="text-decoration:underline;text-decoration-color:#000000;">Schedule I</u> hereto. The delivery of the Existing Notes by each Purchaser will be complete upon receipt by the Trustee on the Closing Date of a DWAC request through DTC (and the Trustee&#8217;s confirmation of such DWAC request) and any other required documents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>On the Closing Date, the Company, or Trustee at the Company&#8217;s direction, will (i) cause the Exchange Notes to be credited to the DTC accounts identified by each Purchaser (as specified on its signature page hereof) against delivery of the Existing Notes, as set forth on <u style="text-decoration:underline;text-decoration-color:#000000;">Schedule&#160;I</u> hereof and (ii) cause the payment of the Cash Consideration and the Accrued Interest by wire transfer of immediately available funds to the accounts previously provided in writing by each Purchaser.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>The Purchasers shall cease to own the Existing Notes exchanged pursuant to <u style="text-decoration:underline;text-decoration-color:#000000;">Section&#160;1.1</u> hereto as of the crediting of the Exchange Notes to the DTC accounts identified by the Purchasers and the payment of the Cash Consideration and the Accrued Interest by wire transfer as provided in <u style="text-decoration:underline;text-decoration-color:#000000;">clause&#160;(b)</u> above, and the Company shall be entitled to instruct the appropriate parties to immediately thereafter cancel the Existing Notes on the books and records of the Company.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;white-space:nowrap;">Article&#160;II</font><u style="text-decoration:underline;"><a name="sty_hcu_2"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></u><u style="text-decoration:underline;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company represents and warrants to, and agrees with, each Purchaser, as of the Closing Date, as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.1</font><u style="text-decoration:underline;">Existence and Power</u><font style="line-height:1.19;">. The Company is a duly incorporated and validly existing corporation and in good standing under the laws of the State of Delaware and has the </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">corporate power and authority to own its properties and conduct its business as currently conducted. The Company&#8217;s subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Subsidiaries</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221; and, together with the Company, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Company Parties</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;), are duly organized and validly existing and in good standing under the laws of Israel and the Netherlands, respectively, and have the organizational power and authority to hold their respective properties and conduct their businesses as currently conducted. The Company does not have any &#8220;significant subsidiary&#8221; as defined in Rule 1-02 of Regulation S-X that is not listed above.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.2</font><u style="text-decoration:underline;">Authorization and Enforceability</u><font style="line-height:1.19;">. The execution, delivery and performance of this Agreement and of the U.S. security agreement (the &#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">U.S. Security Agreement</u><font style="line-height:1.19;">&#8221;), perfection certificate, copyright security agreement, patent security agreement, trademark security agreement, Israeli Stock Pledge, share transfer deed, Israeli Floating Charge and IP charge, each dated as of the Closing Date (collectively, with any other documentation pursuant to which a lien is granted to the Collateral Agent, the &#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Security Documentation</u><font style="line-height:1.19;">&#8221;), and each other document, instrument or agreement executed and delivered by the Company Parties in connection with this Agreement and the transaction contemplated hereby has been duly authorized by all necessary action on the part of the Company Parties, and this Agreement, the Security Documentation and each other document, instrument or agreement executed and delivered by the Company Parties in connection with this Agreement and the transactions contemplated hereby, when duly executed and delivered by the parties hereto and thereto, will be the legal, valid and binding obligation of the Company Parties, enforceable against the Company Parties in accordance with its terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors&#8217; rights generally from time to time in effect and to general principles of equity).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.3</font><u style="text-decoration:underline;">Capitalization</u><font style="line-height:1.19;">. All issued and outstanding shares of common stock, par value $0.001 per share, of the Company (the </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Common Stock</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">) have been duly authorized and validly issued and are fully paid and nonassessable, and none of the outstanding shares of Common Stock were issued in violation of any preemptive or similar rights of any securityholder of the Company. The issued and outstanding shares of capital stock or other equity interests of each of the Company&#8217;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company free and clear of any security interests, liens, encumbrances, equities or claims of any third party, except as described in the Reports (as defined below).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.4</font><u style="text-decoration:underline;">Valid Issuance of Exchange Notes; Enforceability of Exchange Notes and Exchange Notes Indenture</u><font style="line-height:1.19;">. The Exchange Notes Indenture and the Exchange Notes have been duly executed by the Company and, when authenticated by the Exchange Notes Trustee in accordance with the Exchange Notes </font><font style="line-height:1.19;text-decoration:none;">Indenture</font><font style="line-height:1.19;">, and delivered and paid for as provided herein, will be the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms and entitled to the benefits of the Exchange Notes Indenture (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors&#8217; rights generally from time to time in effect and to general principles of equity); the number of shares of Common Stock initially issuable upon conversion of the Exchange Notes at the initial conversion rate set forth in the Exchange Notes Indenture will be duly authorized and, when issued upon conversion of the Exchange Notes in accordance with the Exchange Notes Indenture, will be validly issued, fully </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"><a name="_Hlk79176038"></a>paid and nonassessable; the maximum number of shares of Common Stock initially issuable upon conversion of the Exchange Notes (including the maximum number of additional shares that may be issued in connection with a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-decoration:none;">Make-Whole Adjustment Event</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> assuming all conversions are settled solely in shares of Common Stock and the &#8220;Make-Whole Premium&#8221; assuming settlement solely in shares of Common Stock (the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;text-decoration:underline;text-decoration-color:#000000;">Maximum Number of Shares</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">)) has been duly authorized and, when issued upon conversion of the Exchange Notes in accordance with the Exchange Notes Indenture, will be validly issued, fully paid and nonassessable; the Exchange Notes Indenture has been duly authorized and, assuming due authorization, execution and delivery thereof by the Trustee and the Collateral Agent, when executed and delivered by the Company, will constitute a legal, valid, binding instrument enforceable against the Company in accordance with its terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors&#8217; rights generally from time to time in effect and to general principles of equity); the Board of Directors of the Company has duly and validly adopted resolutions reserving a number of shares of Common Stock for issuance upon conversion of the Exchange Notes equal to the Maximum Number of Shares; and such shares of Common Stock are not subject to any preemptive or similar right.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.5</font><u style="text-decoration:underline;">Non-Contravention/No Consents</u><font style="line-height:1.19;">. The execution and delivery of this Agreement, the Exchange Notes Indenture, the Third Supplemental Indenture and the Exchange Notes, the consummation of the transactions herein and therein contemplated, and the fulfillment of the terms hereof and thereof, will not conflict with, result in a breach or violation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, (a) the Certificate of Incorporation, Bylaws or any comparable constituting documents of the Company or any of its subsidiaries; (b) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is subject (collectively, &#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Contractual Obligations</u><font style="line-height:1.19;">&#8221;), other than the terms of the Existing Indenture contemplated to be amended by the Third Supplemental Indenture in connection with the closing of the Exchange; or (c) any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of its subsidiaries or any of its or their properties (collectively, &#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Laws</u><font style="line-height:1.19;">&#8221;), except, in the cases of clauses (b) and (c), as would not, singly or in the aggregate, have a material adverse effect on the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business (a </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Material Adverse Effect</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">). Subject to the Aggregate Share Cap (as defined in the Exchange Notes Indenture), no stockholder approval is required under the rules of the NYSE American LLC (</font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">NYSE American</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">) in connection with the issuance of the Exchange Notes.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.6</font><u style="text-decoration:underline;">Minimum Liquidity</u><font style="text-decoration:none;">. </font><u style="text-decoration:underline;"><a name="_Hlk79421430"></a></u><font style="text-decoration:none;">Following the Closing and the payment of the Cash Consideration by the Company, the Company will hold unrestricted cash not less than the amount necessary to redeem or repay at maturity all of the Existing Notes that remain outstanding following the Closing Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.7</font><u style="text-decoration:underline;">Secured Party Rights; Ownership of Property; Liens.</u></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Protalix Ltd. is authorized to pledge to Altshuler Shaham Trust Ltd., as security trustee, for the benefit of the Exchange Notes Trustee (on behalf of the Purchasers), a security interest in all (or a portion) of its assets, subject to the approval of the Israeli National Authority for Technological Innovation (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Israeli Innovation Authority</u>&#8221;) and in accordance with the provisions of the Israeli Encouragement of Research, Development and Technological Innovation in Industry Law, 5744-1984 (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Innovation Law</u>&#8221;);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>the Company has good and marketable title to all personal property owned by it, subject to no Liens other than Permitted Liens, is authorized to pledge to the Collateral Agent, for the ratable benefit of the Secured Parties, and grant a security interest and Lien in all of the Collateral pledged by it pursuant to the U.S. Security Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>the Company and each of its subsidiaries has title in, or a valid leasehold interest in (or sub-leasehold interest in or other right to occupy), all its real property owned or occupied by it (except insofar as marketability may be limited by any laws or regulations of any governmental authority affecting such assets), and none of such property is subject to any Lien except as not prohibited by this Agreement; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>the execution and delivery of this Agreement, the Exchange Notes Indenture and the Exchange Notes, the consummation of the transactions herein and therein contemplated, and the fulfillment of the terms hereof and thereof, will not result in, or require, the creation or imposition of any Lien on any of their respective properties or revenues pursuant to any requirement of Law or any Contractual Obligation (other than the Transaction Liens (as defined in the U.S. Security Agreement) and the Liens created under the Israel Security Agreements (as defined in the Exchange Notes Indenture)).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.8</font><u style="text-decoration:underline;">SEC Reports</u><font style="line-height:1.19;">. The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as amended, and all other reports filed by the Company with the Securities and Exchange Commission (the </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">SEC</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">) pursuant to Section 13(a), Section 14 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Exchange Act</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">), since December 31, 2020 and prior to the date hereof (collectively, the </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Reports</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">), when they were filed with the SEC, complied as to form in all material respects with the applicable requirements under the Exchange Act, and did not, when such Reports were so filed, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Prior to the Closing, there shall not have occurred a Material Adverse Effect or any development involving a prospective Material Adverse Effect in the general affairs, business, properties, management, financial condition or results of operations of the Company from that set forth in the Reports.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.9</font><u style="text-decoration:underline;">Form 8-K</u><font style="text-decoration:none;">. No later than 9:00 a.m., New York City time, on the first business day following the date of this Agreement, the Company shall file with the SEC a current report on Form 8-K announcing the Exchange, including all required exhibits thereto, which current report the Company acknowledges and agrees will disclose all material terms of the Exchange.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.10</font><u style="text-decoration:underline;">No Brokers</u><font style="line-height:1.19;">. Neither the Company nor any of its subsidiaries nor any of their respective officers, directors, employees or agents has incurred any liability for any commissions or other remuneration in connection with the Exchange.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.11</font><u style="text-decoration:underline;">Section 3(a)(9) Exemption</u><font style="line-height:1.19;">. It is not necessary in connection with the Exchange, in the manner contemplated herein, to register the issuance of the Exchange Notes under the Securities Act in reliance on the exemption from registration set forth under Section 3(a)(9) of the Securities Act. Neither the Company nor anyone acting on the Company&#8217;s behalf has received any commission or remuneration directly or indirectly in connection with or in order to solicit or facilitate the Exchange.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.12</font><u style="text-decoration:underline;">No Restrictions on Sale</u><font style="line-height:1.19;">. Assuming the accuracy of the Purchasers&#8217; representations and warranties hereunder, the Exchange Notes will, as of the Closing Date, be free of any restrictive legend or other restrictions on resale by the Company and will be issued in book-entry form, represented by permanent global certificates deposited with, or on behalf of, The Depositary Trust Company represented by the unrestricted CUSIP assigned to the Company&#8217;s Common Stock.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.13</font><u style="text-decoration:underline;">Properties</u><font style="line-height:1.19;">. Each of the Company and its subsidiaries owns or leases all such properties as are reasonably necessary to the conduct of its operations as presently conducted.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;2.14</font><u style="text-decoration:underline;">Intellectual Property</u><font style="line-height:1.19;">. The Company and its subsidiaries own, possess, license or otherwise have adequate rights to use, on reasonable terms, all patents, trademarks, service marks, trade names, copyrights and copyrightable works, licenses, inventions, trade secrets, technology, know-how (whether or not patentable) and other intellectual property or proprietary rights (including all registrations and applications for registration of, and all goodwill associated with the foregoing) (collectively, the </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">) necessary for the conduct of the Company&#8217;s and its subsidiaries&#8217; businesses as now conducted. Except as would not, singly or in the aggregate, have a Material Adverse Effect: (a) there are no rights of third parties to any such Intellectual Property except as disclosed in the Reports; (b) to the Company&#8217;s knowledge, there is no infringement, misappropriation or other violation by third parties of any such Intellectual Property; (c) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging the Company&#8217;s or any of its subsidiaries&#8217; rights in or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (d) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, enforceability or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (e) there is no pending or, to the Company&#8217;s knowledge, threatened action, suit, proceeding or claim by others that the Company or any of its subsidiaries (or the conduct of their respective businesses) infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, and the Company is unaware of any fact which would form a reasonable basis for any such action, suit, proceeding or claim; (f) there is no U.S. patent or published U.S. patent application which contains claims that have (or may have) priority over or dominate (or may dominate) any Intellectual Property owned by or licensed to the Company or that interferes with the issued or pending claims of any such Intellectual </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Property; and (g) there is no prior art of which the Company is aware that may render any U.S. patent held by the Company invalid or any U.S. patent application held by the Company unpatentable which has not been disclosed to the U.S. Patent and Trademark Office.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;white-space:nowrap;">Article&#160;III</font><u style="text-decoration:underline;"><a name="sty_hcu_3"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></u><u style="text-decoration:underline;">REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Each Purchaser, severally but not jointly, represents and warrants to, and agrees with, the Company, as of the Closing Date, as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.1</font><u style="text-decoration:underline;">Existence and Power</u><font style="line-height:1.19;">. Such Purchaser is duly organized and validly existing under the laws of the jurisdiction of its organization and has all requisite power and authority to enter into and perform its obligations under this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.2</font><u style="text-decoration:underline;">Authorization</u><font style="line-height:1.19;">. The execution, delivery and performance of this Agreement and each other document, instrument or agreement executed and delivered by such Purchaser in connection with the transactions contemplated hereby has been duly authorized by all necessary action on the part of such Purchaser, and this Agreement and each other document, instrument or agreement executed and delivered by such Purchaser in connection with the transactions contemplated hereby, when duly executed and delivered by the parties hereto and thereto, is a valid and binding obligation of such Purchaser, enforceable against it in accordance with its terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors&#8217; rights generally from time to time in effect and to general principles of equity). Such Purchaser has the full right, power, legal capacity and authority to sell and transfer the Existing Notes and to enter into and perform its obligations under this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.3</font><u style="text-decoration:underline;">Governmental Authorization</u><font style="line-height:1.19;">. As of the date hereof, no permit, authorization, consent or approval of or by, or any notification of or filing with, any Person (governmental or private) is required to be obtained or made by such Purchaser in connection with the execution, delivery and performance by it of this Agreement, the consummation by it of the transactions contemplated hereby or thereby, or the issuance or delivery to it by the Company of the Exchange Notes, other than a filing on a Schedule 13G or 13D (or 13G/A or 13D/A), if applicable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.4</font><u style="text-decoration:underline;">Non-Contravention/No Consents</u><font style="line-height:1.19;">. The execution, delivery and performance of this Agreement will not conflict with, violate or result in a breach of any provision of, or constitute a default under, or result in the termination of or accelerate the performance required by (a) any provision of the organizational documents of such Purchaser, (b) any mortgage, note, indenture, deed of trust, loan agreement or other agreement or instrument to which such Purchaser is a party or by which such Purchaser is bound or to which any of the property or assets of such Purchaser is subject; or (c) any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, or administrative agency having jurisdiction over such Purchaser or any of its properties or assets, other than any such conflict, violation, breach, default, termination and acceleration under </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">clauses (b) and (c) that would not reasonably be expected to materially adversely impact the ability of such Purchaser to consummate the transactions contemplated hereby.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.5</font><u style="text-decoration:underline;">No Brokers</u><font style="line-height:1.19;">. Such Purchaser has not employed any broker or finder in connection with the transactions contemplated by this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.6</font><u style="text-decoration:underline;">Purchaser Status</u><font style="line-height:1.19;">. Such Purchaser acknowledges that (a) it meets the definition of &#8220;qualified institutional buyers&#8221; as defined in Rule 144A(a)(1) under the Securities Act; and (b) is not an entity formed for the sole purpose of acquiring the Exchange Notes. Such Purchaser is not an &#8220;affiliate&#8221; of the Company within the meaning of Rule 144 under the Securities Act.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.7</font><u style="text-decoration:underline;">Company Information</u><font style="line-height:1.19;">. Such Purchaser represents that in connection with this Agreement and the Exchange contemplated hereby it is relying solely on the information relating to the Company&#8217;s business, finances and operations contained in the Reports and in certificates delivered by the Company pursuant to this Agreement, and further acknowledges that the Company makes no representation or warranty with respect to any matters relating to the Company, its business, financial condition, results of operations, prospects or otherwise, except to the extent expressly provided in Article II hereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.8</font><u style="text-decoration:underline;">Undertaking</u><font style="line-height:1.19;">. Each Purchaser undertakes (a) to observe all the requirements of the </font><font style="line-height:1.19;text-decoration:none;">Innovation Law</font><font style="line-height:1.19;"> and the provisions of the applicable regulations, rules, procedures and benefit plans, as applied to Protalix Ltd. and as directed by the research committee of the Israeli National Authority for Technological Innovation (the </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">Research Committee</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;"> and the </font><font style="line-height:1.19;">&#8220;</font><u style="line-height:1.19;text-decoration:underline;text-decoration-color:#000000;">IIA</u><font style="line-height:1.19;">&#8221;</font><font style="line-height:1.19;">, respectively) relating to the prohibitions on the transfer of know-how and/or production rights; and (b) as a stockholder of the Company, to make all reasonable efforts to cause Protalix Ltd. to observe strictly all the requirements of the Innovation Law and the provisions of the applicable regulations, rules, procedures and benefit plans, as applied to Protalix Ltd. and as directed by the Research Committee, in particular those requirements relating to the prohibitions on the transfer of know-how and/or production rights.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.9</font><u style="text-decoration:underline;">Risks of Investment</u><font style="line-height:1.19;">. Such Purchaser fully understands the risks relating to an investment in the Exchange Notes. Such Purchaser is able to bear the economic risk of holding the Exchange Notes for an indefinite period (including total loss of its investment), and has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risk of its investment.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.10</font><u style="text-decoration:underline;">No Encumbrances</u><font style="line-height:1.19;">. Such Purchaser is the sole and exclusive holder of the Existing Notes free and clear of all liens, pledges, hypothecations, claims, restrictions or encumbrances, and no other Person, firm or corporation has any interest whatsoever in the Existing Notes (other than pledges or security interests that such Purchaser may have created in favor of a prime broker under and in accordance with its prime brokerage agreement with such broker). The Exchange provided for herein will vest in the Company valid and absolute title to the Existing Notes, free and clear of any and all encumbrances, liens, pledges, hypothecations, restrictions, claims, options, agreements and conditions.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.11</font><u style="text-decoration:underline;">Section 3(a)(9) Exemption</u><font style="line-height:1.19;">. Such Purchaser acknowledges that in connection with the Exchange, in the manner contemplated herein, the Company intends to rely on the exemption from registration set forth under Section 3(a)(9) of the Securities Act. Such Purchaser knows of no reason why such exemption is not available.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.12</font><u style="text-decoration:underline;">Investment Purpose</u><font style="line-height:1.19;">. Such Purchaser is acquiring the Exchange Notes solely for its own account for investment purposes and not with a view to engage in any distribution thereof. Such Purchaser acknowledges that the offer and sale of the Exchange Notes is not registered under the Securities Act, or any state securities laws, and that the Exchange Notes may not be transferred or sold except pursuant to the registration provisions of the Securities Act or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.13</font><u style="text-decoration:underline;">No View to Effecting Exchange</u><font style="line-height:1.19;">. Such Purchaser did not acquire the Existing Notes with a view to effecting the Exchange.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.14</font><u style="text-decoration:underline;">Holding Period</u><font style="line-height:1.19;">. Such Purchaser or, to the best of such Purchaser&#8217;s knowledge, any Person who is not an &#8220;affiliate&#8221; of the Company within the meaning of Rule 144 under the Securities Act has beneficially owned the Existing Notes being exchanged by such Purchaser in the Exchange for a period of at least one year within the meaning of Rule 144(d) under the Securities Act.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.15</font><u style="text-decoration:underline;">Consent</u><font style="text-decoration:none;">. Such Purchaser hereby irrevocably and unconditionally consents to the execution and delivery of the Third Supplemental Indenture, the incurrence of liens securing the Exchange Notes and the execution and delivery of the Exchange Notes Indenture. Such Purchaser agrees to have its custodian or nominee promptly deliver a consent of the Third Supplemental Indenture in accordance with DTC&#8217;s Automated Tender Offer Program procedures and make customary representations and warranties to effectuate such consent.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;3.16</font><u style="text-decoration:underline;">Reliance</u><font style="line-height:1.19;">. Such Purchaser acknowledges that the Company will rely upon the truth and accuracy of the foregoing representations and warranties.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;white-space:nowrap;">Article&#160;IV</font><u style="text-decoration:underline;"><a name="sty_hcu_4"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></u><u style="text-decoration:underline;">CLOSING CONDITIONS</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;4.1</font><u style="text-decoration:underline;">Conditions to the Company&#8217;s Obligations</u><font style="line-height:1.19;">. The Company&#8217;s obligation to complete the Exchange at the Closing shall be subject to the following conditions, any one or more of which may be waived by the Company:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>receipt by the Company of the Existing Notes being exchanged hereunder and satisfaction by each Purchaser of all of its obligations contemplated by this Agreement in connection with the Exchange;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>receipt by the Company of the consent of holders of at least 66 and 2/3% in aggregate principal amount of the Existing Notes to the execution and delivery of the Third Supplemental Indenture;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>the accuracy of the representations and warranties made by the Purchasers in this Agreement; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>no injunction, restraining order, action or order of any nature by a governmental or regulatory authority shall have been issued, taken or made and no action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority of competent jurisdiction that would, as of the Closing Date, prevent or materially interfere with the consummation of the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;4.2</font><u style="text-decoration:underline;">Conditions to the Purchasers&#8217; Obligations</u><font style="line-height:1.19;">. Each Purchaser&#8217;s obligation to complete the Exchange at the Closing shall be subject to the following conditions, any one or more of which may be waived by such Purchaser:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Hlk79176097"></a>the Common Stock shall continue to be listed on the NYSE American as of the Closing Date; there shall have been no suspensions in the trading of the Common Stock as of the Closing Date; and the listing of additional shares notification form with respect to the Maximum Number of Shares shall have been submitted to the NYSE American and the NYSE American shall have confirmed that it has no objection to such notification;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>no injunction, restraining order, action or order of any nature by a governmental or regulatory authority shall have been issued, taken or made and no action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority of competent jurisdiction that would, as of the Closing Date, prevent or materially interfere with the consummation of the transactions contemplated by this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>receipt by such Purchaser of fully executed copies of the Exchange Notes Indenture, the Exchange Notes and the Third Supplemental Indenture, each in form and substance reasonably acceptable to the Purchasers;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>the delivery to such Purchaser by U.S. counsel to the Company of a legal opinion substantially similar in substance to the form of opinion attached as <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit&#160;A</u> hereto;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>the delivery to such Purchaser by Israeli counsel to the Company of a legal opinion substantially similar in substance and form to the opinion delivered by said Israeli counsel pursuant to the execution of the Existing Indenture attached as <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit A</u> hereto;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font>receipt by such Purchaser of a certificate executed by the chief executive officer and the chief financial officer of the Company, dated as of the Closing Date, in substantially the form of certificate attached as <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit&#160;B</u> hereto;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font>receipt by such Purchaser of a certificate of the Secretary of the Company, dated as of the Closing Date, in substantially the form of certificate attached as <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit&#160;C</u> hereto;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>certifying the resolutions adopted by the Board of Directors of the Company approving the Exchange and the reservation and issuance of the shares of Common Stock potentially issuable upon the conversion of the Exchange Notes;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>certifying the current versions of the Certificate of Incorporation and the Bylaws of the Company; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>certifying as to the signatures and authority of the persons signing this Agreement and related documents on behalf of the Company;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font>receipt by such Purchaser of a certificate of good standing for the Company for its jurisdiction of incorporation; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>receipt by such Purchaser of evidence of approval by the Israel Innovation Authority of the transactions contemplated by this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font>receipt by such Purchaser of a duly executed Letter of Undertaking to the IIA, in the form attached hereto as <u style="text-decoration:underline;text-decoration-color:#000000;">Exhibit D</u>, to be held in trust by the Company and delivered to the IIA only upon and subject to such Purchaser&#8217;s (and its affiliates) holdings in the Company being equal to or exceeding 5% of the Company&#8217;s share capital on a fully diluted basis or as otherwise required under the Innovation Law;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font>execution and filing of all amendments to documentation governing security interests with respect to the Existing Notes required to permit registration of liens, on a <i style="font-style:italic;">pari passu </i>basis, under the Security Documentation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font>execution and delivery of the Security Documentation in form and substance reasonably acceptable to the Purchasers;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font>each of the representations and warranties of the Company set forth in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of such date;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font>there shall have been no concern or qualification expressed by the auditors of the Company as to the Company&#8217;s status as a going concern;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font>there shall have been no event, occurrence or development that has resulted in or could reasonably be expected to result in a Material Adverse Effect with respect to the Company; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font>the Outside Date shall not have occurred.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;white-space:nowrap;">Article&#160;V</font><u style="text-decoration:underline;"><a name="sty_hcu_5"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></u><u style="text-decoration:underline;">MISCELLANEOUS</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.1</font><u style="text-decoration:underline;">Definitions</u><font style="line-height:1.19;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>As used herein, the following terms have the following meanings:</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Business Day</u>&#8221; means any day other than a Saturday, a Sunday or any other day on which the Federal Reserve Bank of New York, Wilmington, Delaware or the place of payment is authorized or required by law or executive order to close or be closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Person</u>&#8221; or &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">person</u>&#8221; shall mean an individual, corporation, association, partnership, trust, joint venture, business trust or unincorporated organization, or a government or any agency or political subdivision thereof.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.2</font><u style="text-decoration:underline;">Notices</u><font style="line-height:1.19;">. All notices and other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been given if delivered (a) via email, (b) personally or (c) by facsimile or three Business Days after having been sent by certified mail, return receipt requested, postage prepaid, to the parties to this Agreement at the following address or to such other address either party to this Agreement shall specify by notice to the other party:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>If to the Company:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 144pt;">Protalix BioTherapeutics, Inc.<br>2 University Plaza<br>Suite 100<br>Hackensack, NJ, 07601<br>Attention: Joseph Magnas, General Counsel.<br><a name="sty_hcu_6"></a>Facsimile: 972-4-902-8102<br>E-mail: Joseph.Magnas@protalix.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 144pt;">with a copy to (which shall not constitute notice):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 144pt;">Mayer Brown LLP<br>1221 Avenue of the Americas<br>New York, New York 10020<br>Attention: Anna T. Pinedo<br><a name="sty_hcu_7"></a>Facsimile: 1-212-506-2275<br>E-mail: apinedo@mayerbrown.com</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>if to such Purchaser, at its address as set forth on the signature page to this Agreement or such other address as may from time to time be furnished to the Company in writing.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.3</font><u style="text-decoration:underline;">Further Assurances</u><font style="line-height:1.19;">. Each party hereto shall do and perform or cause to be done and performed all further acts and shall execute and deliver all other agreements, certificates, instruments and documents as the other party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.4</font><u style="text-decoration:underline;">Amendments and Waivers</u><font style="line-height:1.19;">.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">13</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Any provision of this Agreement may be amended or waived if, but only if, such amendment or waiver is in writing and is duly executed and delivered by the Company and Purchasers.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.5</font><u style="text-decoration:underline;">Fees and Expenses</u><font style="line-height:1.19;">. Each party hereto shall pay all of its own fees and expenses (including attorneys&#8217; fees) incurred in connection with this Agreement and the transactions contemplated hereby.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.6</font><u style="text-decoration:underline;">Successors and Assigns</u><font style="line-height:1.19;">. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, provided that neither party may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of the non-assigning party hereto. Notwithstanding the previous sentence, each Purchaser may assign its rights and obligations under this Agreement to one or more of such Purchaser&#8217;s wholly owned subsidiaries that agrees in writing with the Company to be bound by the terms and provisions of this Agreement to the same extent as such Purchaser, but no such assignment shall relieve such Purchaser of its obligations hereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.7</font><b style="font-weight:bold;text-decoration:underline;">Governing Law</b><b style="font-weight:bold;line-height:1.19;">. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.8</font><u style="text-decoration:underline;">Jurisdiction; Waiver of Jury Trial</u><font style="line-height:1.19;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>The parties hereto agree that any suit, action or proceeding seeking to enforce any provisions of, or based on any matter arising out of or in connection with, this Agreement and the transactions contemplated hereby may only be brought in the United States District Court for the Southern District of New York or any New York State court sitting in the Borough of Manhattan in New York City, and each of the parties hereby consents to the jurisdiction of such courts (and of the corresponding appellate courts) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the venue of any such suit, action or proceeding in any of those courts or that any such suit, action or proceeding which is brought in any of those courts has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman';font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;text-decoration:none;">THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY</b><b style="font-weight:bold;">.</b></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">14</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.9</font><u style="text-decoration:underline;">Entire Agreement</u><font style="line-height:1.19;">. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter of this Agreement and supersedes all prior agreements and understandings, both oral and written, between the parties hereto with respect to the subject matter of this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.10</font><u style="text-decoration:underline;">Effect of Headings</u><font style="line-height:1.19;">. The Article and Section headings herein are for convenience only and shall not affect the construction hereof.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.11</font><u style="text-decoration:underline;">Severability</u><font style="line-height:1.19;">. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be deemed to be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforced in accordance with its terms to the maximum extent permitted by law.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.12</font><u style="text-decoration:underline;">Furnishing of Information; Public Information</u><font style="line-height:1.19;">. Until the time the Purchasers own no Exchange Notes, the Company covenants to maintain the registration of the shares of Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. The Company agrees to provide to each of the Purchasers copies of any such reports, and any press releases or other public communications, which include a description of any Purchaser or the transactions contemplated herein not later than two Business Days prior to the filing of such report.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.13</font><u style="text-decoration:underline;">Counterparts; Electronic Execution; Third Party Beneficiaries</u><font style="line-height:1.19;white-space:pre-wrap;">. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures were upon the same instrument. The exchange of copies of this Agreement and of signature pages by facsimile, .pdf or other electronic image-scan transmission shall constitute effective execution and delivery of this Agreement as to the parties hereto and may be used in lieu of the original Agreement for all purposes.  Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. The words &#8220;delivery,&#8221; &#8220;execution,&#8221; &#8220;execute,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Collateral Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. No provision of this Agreement shall confer upon any Person other than the parties hereto any rights or remedies hereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.14</font><u style="text-decoration:underline;">Withholding</u><font style="line-height:1.19;">. On the date hereof (and at any other time or times prescribed by applicable law or as reasonably requested by the Company), each Purchaser shall deliver to the Company a properly completed and duly executed IRS Form W-9 , Form W-8BEN, W-</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">15</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">8BEN-E or other appropriate Form W-8 (or successor form), together with any other information necessary in order to establish an exemption from, or a reduced rate of, U.S. federal income tax withholding, and except to the extent that an exemption or reduction is properly established, all payments to be made by the Company in respect of the Exchange Notes shall be made net of deduction or withholding for or on account of taxes as required by applicable law. Each Purchaser shall promptly notify the Company if at any time such previously delivered IRS forms or information are no longer correct or valid.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.15</font><u style="text-decoration:underline;">Tax Treatment</u><font style="text-decoration:none;">. The Company and the Purchasers agree that the Exchange will constitute a taxable transaction for U.S. federal income tax purposes.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.16</font><u style="text-decoration:underline;">Other Transactions</u><font style="line-height:1.19;">. The Company represents to each Purchaser that the Company has not (a) agreed to, or entered into, any arrangements with any holder of Existing Notes to exchange such Existing Notes for other securities or other consideration, other than pursuant to the Exchange, this Agreement, other concurrent and substantially similar agreements among the Company and holders (other than the Purchasers) of the Existing Notes; or (b) agreed to, or entered into, any arrangements with any Purchaser to provide for the exchange of such Purchaser&#8217;s Existing Notes on terms that differ from the terms set forth in this Agreement; provided, however, that nothing in this Section 5.16 will affect the Company&#8217;s ability to effect any future exchange of any of its securities on terms that may differ from the terms set forth in this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:72pt;text-indent:0pt;white-space:nowrap;">Section&#160;5.17</font><u style="text-decoration:underline;">Miscellaneous</u><font style="line-height:1.19;">. Each representation, warranty, obligation and covenant of each Purchaser herein relates solely to that Purchaser and no Purchaser shall be liable for the inaccuracy of any representation or warranty or any breach of any obligation or covenant of another Purchaser hereunder.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hc_5"></a>[Signature Page Follows]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">16</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:24pt 0pt 0pt 252pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:24pt 0pt 0pt 252pt;"><a name="sty_shb_9"></a>By:<font style="display:inline-block;width:4.26pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:127.03pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br><font style="display:inline-block;width:21.6pt;"></font>Name:<font style="display:inline-block;width:4.01pt;"></font><br><font style="display:inline-block;width:21.6pt;"></font>Title:<font style="display:inline-block;width:10.01pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="sty_hcb_10"></a><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page to Exchange Agreement</i>]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">Print or Type:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, as a Purchaser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Name of Purchaser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><i style="font-style:italic;">(Individual or Institution)</i></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Jurisdiction of Purchaser&#8217;s Executive Offices</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Name of Individual representing Purchaser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Title of Individual representing Purchaser</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">Signature by:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Individual representing Purchaser:</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:31.9pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">Notice Information:</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:71.25pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Address:</font></font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:71.25pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Telephone:</font></font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:71.25pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Facsimile:</font></font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Email: </p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOMINEE/CUSTODIAN</b> (Name in which the Exchange Notes and, if applicable, Common Stock issued upon conversion of the Exchange Notes are to be registered if different than name of Purchaser):</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:5.75pt;padding-right:5.75pt;padding-top:8.65pt;table-layout:auto;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:8.64pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:8.64pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:8.64pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">DTC Number:</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:8.64pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:8.64pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Tax I.D. Number:</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:8.64pt 5.75pt 0pt 5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:12pt 0pt 12pt 0pt;">(If acquired in the name of a nominee/custodian, the taxpayer I.D. number of such nominee/custodian)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:12pt 0pt 12pt 0pt;">* * * Please note that if you are sub-allocating to multiple funds, <br>you must execute a signature page for each fund. ***</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="sty_hc_7"></a><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"><a name="sty_ht1_11"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[<i style="font-style:italic;">Signature Page to Exchange Agreement</i>]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:12pt 0pt 12pt 0pt;">SCHEDULE I</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hcb_12"></a><a name="sty_hcb_13"></a>Amounts of Existing Notes, Principal Amount of Exchange Notes, Amounts of Cash for<br>Accrued Interest, Cash Consideration</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:25.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal Amount of Existing Notes</b></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Principal Amount of Exchange Notes</b></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Consideration</b></p></td></tr><tr><td style="vertical-align:top;width:25.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:25.75%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total:</b></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="sty_hlu_13"></a><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><u style="text-decoration:underline;">Exhibit A</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hc_8"></a>FORM OF MAYER BROWN LLP OPINION AND FORM OF HORN &amp; CO. OPINION</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[Attached]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><u style="text-decoration:underline;"><a name="sty_hlu_14"></a></u><u style="text-decoration:underline;">Exhibit B</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hc_9"></a>FORM OF OFFICERS&#8217; CERTIFICATE</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[Attached]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"><a name="AddUnd"></a><a name="sty_hcb_0"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><u style="text-decoration:underline;"><a name="sty_hlu_18"></a></u><u style="text-decoration:underline;">Exhibit C</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:12pt 0pt 12pt 0pt;">FORM OF SECRETARY&#8217;S CERTIFICATE</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[Attached]</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:12pt 0pt 0pt 0pt;"><u style="text-decoration:underline;">Exhibit D</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:12pt 0pt 12pt 0pt;"><a name="sty_hc_17"></a>FORM OF UNDERTAKING</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[Attached]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>plx-20210812xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/13/2021 11:04:58 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><div style="clear:both;"></div><div style="clear:left;float:left;height:4.5pt;width:0pt;"></div><div style="clear:left;float:left;height:34.9pt;margin-left:2.0pt;margin-right:9pt;width:93pt;z-index:-9223372036603117568;"><div style="height:34.9pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:92.35pt;"><img src="plx-20210812xex99d1001.jpg" alt="Graphic" style="height:34.9pt;width:92.35pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:14pt 0pt 0pt 4.5pt;"><a name="_Hlk18938793"></a><font style="font-size:12pt;font-weight:bold;letter-spacing:-0.15pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:14pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Protalix BioTherapeutics Announces Private Note Exchange</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">CARMIEL, Israel, August&#160;13, 2021 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE&#160;American:PLX) (TASE:PLX), a biopharmaceutical company focused on the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:-0.15pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> plant cell-based protein expression system, today </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">announced the entry into definitive agreements (the &#8220;Exchange Agreements&#8221;) relating to exchanges (the &#8220;Exchanges&#8221;) of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;Existing Notes&#8221;) for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;Exchange Notes&#8221;), $25.90 million in cash and accrued and unpaid interest through the closing date. The Exchanges are expected to close as soon as practicable, subject to satisfaction of certain closing conditions. Following the closing of the Exchanges, the Company expects that $3.27&#160;million aggregate principal amount of the Existing Notes will remain outstanding.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;The exchange of the notes underscores Protalix&#8217;s commitment to addressing our capital structure while continuing development of our pegunigalsidase alfa program and our early pipeline,&#8221; said Dror Bashan, Protalix&#8217;s President and Chief Executive Officer. &#8220;We believe that the participation of so many of our institutional note holders, including funds managed by Highbridge Capital Management, LLC, UBS O&#8217;Connor LLC, Citigroup Global Markets, Whitebox Advisors, and Tulip Capital,</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> is a telling vote of confidence in Protalix.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Like the Existing Notes and at equal priority, the Exchange Notes will be secured by perfected liens on all of the material assets of the Company and its subsidiaries. Interest on the Exchange Notes will be payable semi-annually at a rate of 7.50% per annum. The Exchange Notes will mature three years after issuance, unless earlier purchased, converted, exchanged or redeemed, and will be guaranteed by the Company&#8217;s subsidiaries.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Holders may require the Company to repurchase their Exchange Notes upon the occurrence of certain events that constitute a fundamental change under the indenture that will govern the Exchange Notes (the &#8220;Indenture&#8221;) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Holders may convert their Exchange Notes at any time prior to the close of business on the business day immediately preceding the stated maturity date of the Exchange Notes. Upon conversion, the Company may, at its election, deliver shares of the Company&#8217;s common stock (&#8220;Common Stock&#8221;), cash or a combination of shares of Common Stock and cash based on the applicable conversion rate. However, until the Company obtains stockholder approval to issue additional shares of Common Stock upon conversion of the Exchange Notes, the Company will be required to settle at least a portion of its conversion obligation in cash. The Company intends to seek stockholder approval promptly in order to be able to settle conversions of the Exchange Notes in Common Stock.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The initial conversion rate will be based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August 13, 2021.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The Indenture includes covenants customary for instruments of this type, including, without limitation, restrictions on the Company&#8217;s ability to incur additional indebtedness, create liens on its properties, pay dividends and make restricted payments or certain investments, and also requires the Company to apply a portion of the proceeds from certain asset sales or licensing arrangements to repay the Exchange Notes, in each case subject to certain exceptions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;This exchange transaction allows us to continue to advance our lead drug candidate, PRX-102, towards approval and to progress our early stage pipeline candidates,&#8221; said Eyal Rubin, Protalix&#8217;s Sr. Vice President and Chief Financial Officer.</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. The offer and sale of the Exchange Notes and the shares of Common Stock issuable upon conversion of the Exchange Notes, if any, will not be registered under the Securities Act of 1933 or any state securities laws, and unless so registered, the Exchange Notes and such shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act of 1933 and applicable state laws.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based protein expression system, ProCellEx. Protalix was the first company to gain U.S.&#160;Food and Drug Administration (FDA) approval of a protein produced through a plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human </font><font style="font-family:'Times New Roman','Times','serif';">&#945;&#8211;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Galactosidase-A protein for the treatment of Fabry disease; alidornase alfa</font><font style="font-family:'Times New Roman','Times','serif';">,</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of refractory gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa, and with SarcoMed USA, Inc. for the worldwide development and commercialization of PRX-110 for use in the </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</font></p><p style="color:#373737;font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="color:#000000;font-weight:bold;">Forward-Looking Statements Disclaimer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:12pt;text-indent:0pt;margin:0pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks relating to our ability to complete the Exchanges in a timely manner; the risks that the FDA may not hold a Type A Meeting for the PRX-102 BLA on a timely manner; risks related to the timing and progress of the preparation of an updated BLA addressing the complete response letter; risks related to the timing, progress and likelihood of final approval by the FDA of a resubmitted BLA for PRX-102 and, if approved, whether the use of PRX-102 will be commercially successful; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, European Medicines Agency or other health regulatory authorities, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="color:#373737;font-weight:bold;">Investor Contact</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#373737;">Chuck Padala</font><font style="color:#373737;">, Managing Director</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#373737;">LifeSci Advisors</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#373737;">646-627-8390</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">chuck@lifesciadvisors.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Source: Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">###</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20210812xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210812xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ 9@# 2(  A$! Q$!_\0
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MM=M\-/\ DG^E_P#;7_T:]<3\:O\ D):/_P!<9?YK7;?#3_DG^E_]M?\ T:]
M'6T444 </\4-=_LCPH]M&^VXOV\A?]S^,_EQ_P "%<O\'="WSW>NS)\L?^CV
M_P!3@L?P&T?BU<[\1=8;Q!XR>VMOWL5HWV6%5_B?/S8]RW'_  $5[9X;T=-
M\/V6F1_\L8_WC?WG/+'\6)H Y/XL:'_:/AM=1B7]_8-O;_KFV WY<-^!K)^#
MNN[TO="F?[O^D6_T. X_ [3_ ,"->I7$$5U;RP3*&BE4HZ^H(P1^5?.49N/
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M=\>?\B-K7_7JU>;?!G_D9-0_Z\__ &=:])\>?\B-K7_7JU>;?!G_ )&34/\
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MYTDF-Y=>FP')'T)*K]#7=?&#662QM=$@W;YV\^;;_<4_*/Q;G_@-6_A+H/\
M9WA^75)TVSW[?+N[1+D+],G<?IB@#T6BBB@ HHHH \*^+.@_V?XD348T_P!'
MOUW-_LR+@-^8VGZDUZ;X"U[_ (2#PI:SR-ONH?W%Q_OKCG\1@_C2>/M!_P"$
M@\*74$:!KJ']_;_[Z@\?B,C\:\T^%&LOIOB-].F#K!?KA=RG"R+DK^8W#ZXH
M ]2\>?\ (C:U_P!>K5YM\&?^1DU#_KS_ /9UKTGQT/\ BAM8_P"O9J\%T/7-
M7\.7<L^F-Y4LD>QF:$/QD'N/44 ?3E%> ?\ "R_&/_/ZO_@*G_Q-'_"R_&/_
M #^K_P" J?\ Q- 'O]>9?&?_ ) .F?\ 7V?_ $!JQ?"7CSQ-JOBO3;&\N=UK
M/(1(OV=1QM8]0..0*V_C,K-H6F[49O\ 2S_Z U %GX._\B?<?]?K_P#H"5Z%
M7GWP?5D\(7 9-O\ IK_^@)7;7]_!IMH]S<.%C3]?0#U- F[:L;J6HVVE63W-
MT^U%_,GL!ZFO+-2U*\\2:J@",S,VV&!>=H_Q]3_04NK:K>>(=13Y&^]MAMUY
MQG^9/<UW?AGPU%HL'FS;7O)!\S?W!_=']3WI;G$VZ\K+8?X;\.1:+!YL@5[R
M0?O),=!_='M_/\JA\3^)TTB,VUNRM>.OX1KZGW]!_DO\3^)4T:#R(?GO)!\J
M_P!P?WC_ $'>N%TC2;SQ#J+_ #MLW;KB9N<9_FQ]*"JD^7]W3W%T31;KQ%?/
MO=O*W;IIFYZ]N>I->IV5E;V%HEM;QA(H^BC^=)8V%OIMHEM;H%C7]?4GU-6Z
M+&M&DH+S"L_5M)M=8LFMKA?=67[R'U%:/:DIFK2:LSQZZM+_ ,-:RGS>5+&V
MZ.1?NN/7W'8BO1O#^OV^NVN\?)<1_P"LC]/<>H-6-9TBVUFQ:WG'S=8Y .4/
MJ/\ #O7E\L6H^&]8R/W4\?S*R_=<?U!]*6QQM.A+3X6>QYHK'T'7(-:M/,3Y
M)U_UD7]T_P!1[T4SM335S9HKR#3?B/XSUCS6T[0[.Z\K'F>7&YVYSC^/V-6Y
M/B!XRTQ//U7PI^X7EFCCD4*/=OF _&@9ZI17/>%_%FG>*K1Y;(LDL>/.@DQO
M3/0\=0<'!'_UJOZ[>R:9X?U*_A16EMK6695?H2J%@#CMQ0!I45S'@?Q!=>)_
M#W]HW<444OG.FV'(7 QCJ2:Z>@ HHHH **** "BN*MO%U_+\3KKPRT$ LH4W
M++M;>?W:MUSCJQ[5VM !17$V'BZ_NOB5>^&W@@%I;1EED56WG"H>3G'\9[5V
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1BBB@!-M+17$Z7XNO[[XCZAX>D@@6TMHV9)%5M[8V=><?Q'M0!VN*
M *6N*TOQ;?WWQ$U+P])! MI;1LR2*K;VQLZ\X_C/:@#M:*** "BBB@ I-M+1
M0 F**6B@#RGX*?ZC6O\ KI%_)J]6KY_\"^(=9T*.]72M#EU3SF3S/+5SLQNQ
M]T'KD]?2NCU+XA^-4M'V>&);+_IM):ROM]^0!^= #=+ABT?XY2V>G?+:S;UD
MC7HNZ'S"/IN ^F<5Z=KDEK%H&H2WT32V:6TC7$:]7C"DL.HZC(ZUYA\*#I=S
MJMU?7>H-/K\V[Y9./E)R6!_B8]_0=L5Z-XO_ .1)UW_L'7'_ *+:@"IX+NM&
MN_#_ )N@V;VMEYSCRY.&W\9/4_SKHF=8T9F;:J\DFN'^$G_(D+_U\R?TK*^(
MNI7NL:[8>#=,EVO<X:X;V.2 ?8*"Q'?B@#1U;XK:'8S_ &6RCN-1E^[NMP F
M?8GK^ (J&R^+ND/=?9]1L;VQ_P!MEW@?4#YOT-=3X?\ #&E^&K!;>QMU#;?W
MD[*"\A]2?Z=!5O5='L-:M'M=0M8IXF_O+RON#U!]Q0!9M;NWOK6.YM9DE@D7
M<DD;95A]16)XH\9Z;X2-K_:,5PWVG?Y?DJI^[C.<L/[PKB/#[77@'Q__ ,(W
M/.\NE7^&MV;^$G(4^QR"AQU^4UZK)#%+_K(D?']Y0?YT >&6WC72HOB==>)F
M2Z^Q31[57:N__5JG3=CJI[UZCX8\;Z7XMGN(M/BN5:V4,_G*HZD@8PQ]#7'6
M,$7_  OK4(O*3RO)^[M&W_41]J]3C@BB'[N)$_W5 _E0!Y38W5O9?&O7;JZE
M6*WCMV:21VP%&R*M.Y^+VG>>\6G:7?WB+_RT50OXXY./J!7*:IH?_"1?&2]T
MYG9;>28--M_YYK$K$?C@#\17M%A86FFVJ6ME;Q00+]U(UP/_ *Y]Z .7\._$
MG1/$%TMGF6SNVX6.XQASZ!@<9]C@UV=>>_$SPI:WVA7&L6\2Q:A:+YK21\,Z
M#[P..I Y!Z\>];W@76)=<\(6%Y</NN-IBF;U925S]2 #^- '0NZQHSLX55Y8
MGL*X35/BOH=E=_9;*.XU&7INMU&S\">3]0"*SOB#J%YKGB.R\%:;+Y?V@![I
MA_=.3@^P4%B._%=KH'AS3/#EDL&GVZIQ^\F;EY#ZLW?Z=!VH Y6Q^+NCRW0M
M]1LKS3F;^*1=RK]<<C\J[VWN8+VWCGMY4EAD7<LD;95A[$56U72+#6K1K74+
M6*>)O[R\K[@]0?<5YOX:DNO WCU_"T\[2:7>_/:LW\);.T^Q)!0XZD \4 >D
M:OJD&BZ5<:C<HS16Z;W6/!;'MDBN8N/B;H%MHUOJ#?:6:XW>7;;!YN%8J2><
M 9!Y)YK4\>_\B+K'_7N?YBN%^%_A"RO=._MS4X%N3YA2UCD^9%53RV#P3NS]
M,9[T >B>&->B\2Z'%JL-NT"2LZA&()^5BO;Z5)K6OZ;X?M?M.IW2P(W"J>6<
M^@4<FK<TD&GV,T[;8H((R[;1C"J,G]!7E/A72&^(>OWOB375:6RAD\JWMS]W
MCD+_ +J@C/\ >).>X(!JO\8;)Y'^Q:+?SQ+_ !\#]!FMKP[\1M#\13K:H\EK
M=MPL-P -Y] P)!/MP?:NKA@BMX5AAB2*)1A5C4*H^@'2N6\8^";+Q+8RR0Q+
M!JJ+F&Y7Y2Q'(5B.H/KU'4>X!=T7Q;8:YK.H:9:QW"SV#%96D4!3ABIQ@G/(
M]!4OB;Q19>%;&*\OXIWBDD\I?)4$YVENY'&%->=?"&267Q)K3W&[[0T8:3=]
M[>7.[/OG-;/QG_Y%?3_^OX?^BWH Z+7/'.B>'X(Y+V=FEE0/';1KNDP>A(S@
M#W)%<R?C':+^\?0KY;?_ )Z;E_\ U?K4_@'P;%]DB\0ZROVS4[M1+&9OF\I"
M!C@_Q$8/L, 8Q7HC(K)M/W: ,+P_XOT;Q/&W]FW7[U1EH9!L<>^.X]QD5OUY
M;X_\))I")XI\/K]CN[20/,L/"L"<;P.@(SR.A!.??NO#.M+X@\/66IJFUIH_
MWB_W6!PP_,&@"_>7EOI]K+=7<Z001KEI)&PJUP=W\7M(6=X-.L+R^V_QJNP-
M] ?F_,"LK5_M'Q"^(#Z'YC)HVF,3-M_C*G#'ZECM'H 37IFFZ78:1:+:V%K%
M;PK_  QKC\2>I/N: .0TCXK:#J$_V:[6;3ION_Z0!LS[L/N_\" KNP=PW+6)
MXB\+Z7XEL6@O;=?-V_N[A5&]#Z@^GL>#7(_#?5;W3]2O_!^IMNELLFW;_8!
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M*]U=K\K0VV#L/H6)"@^V<^U5?B9XEN-$T6*SL'9;^_8QQLO54&-Q'N2RJ/\
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M_P#:;UE?"6T;3_%6NV3,KM;KY3,O0E9"IQ[<5K?&D_\ %+Z?_P!?H_\ 1;T
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LC6;RM]YO+ +?4C&:W:* ,_3='TW2(VCT^Q@MD;[WEQ@;OJ>I_&BM"B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20210812.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/13/2021 11:05:07 AM-->
<!--Modified on: 8/13/2021 11:05:07 AM-->
<xsd:schema targetNamespace="http://protalix.com/20210812" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plx="http://protalix.com/20210812">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210812_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210812_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20210812_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/13/2021 11:05:07 AM-->
<!--Modified on: 8/13/2021 11:05:07 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20210812.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20210812_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/13/2021 11:05:07 AM-->
<!--Modified on: 8/13/2021 11:05:07 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20210812.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20210812.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637644495072700748" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637644495072700748" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637644495072700748" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637644495072700748" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637644495072700748" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637644495072700748" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637644495072700748" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_637644495072700748" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637644495072700748" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637644495072700748" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637644495072700748" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637644495072700748" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637644495072700748" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637644495072700748" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637644495072700748" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637644495072700748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637644495072700748" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637644495072710735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637644495072710735" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637644495072710735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637644495072710735" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637644495072710735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637644495072710735" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637644495072710735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637644495072710735" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637644495072710735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637644495072710735" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637644495072710735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637644495072710735" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637644495072710735" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637644495072710735" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plx-20210812x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210812.xsd" xlink:type="simple"/>
    <context id="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_hmDQnI4EXEKQVxHjSXGb5A_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_foOeh9_Dz0C-u_-xVncb-Q_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_i_H4bj5e7EKmLi068hYR0w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_Q-hSX1_JgEuxX8LubSBLEg">2021-08-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_N5fbASVY3UmqBnyQagWcOA">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_8ANLRlDAEEazBNavx_Ve2Q_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_chCa6R_LWEGhILB-s9LiXQ_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_YtOjwL8cxE-xQpx4spRK3w_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_UGoKOL8KVE-u8azBVBYJiQ_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_Cybi8LbBn0Wi1jiAtAGrUQ_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_nb0xXsh7n0KfEsZS9tCWaQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_Af7S9YQNEESYUwdyzYnI8g">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_J8QxUBbeIE-bK4Lz7srDEQ_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_KnMSNrGQ9kq1sj8WJaNa0Q">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_q1OiuCxgA06eGDwfy1tZGA">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_0hkmS27GFUCCa6bowPsjNg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_62DRgwsjkEiHbKCEy5ngfA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_TEAp8lVDy0WKzcSwPBFBQg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_g8H7dux98U23Bb8h-hbUyg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_2eEXGvSdm0y7iYvf2NSJRQ_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_hY8de9PVUEGw5mLVCzjQbw_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Tc_ij1Mfal7T0iJS88Il81C4A_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ"
      id="Narr_gRO7vsnxGE2KKMhi5ex8NA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139912572155480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 12,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M;%!+ 0(4 Q0    ( *DX#5/4I^AG[@   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *DX#5.97)PC$ 8  )PG
M   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ J3@-4[TW:<)7!   "Q$  !@              ("!#0@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *DX#5.?H!OPL0(  .(,
M   -              "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MJ3@-4Y>*NQS     $P(   L              ( !=@\  %]R96QS+RYR96QS
M4$L! A0#%     @ J3@-4QPX9>H_ 0  / (   \              ( !7Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *DX#5,D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( *DX#5-ED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20210812x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20210812x8k.htm">plx-20210812x8k.htm</File>
    <File>plx-20210812.xsd</File>
    <File>plx-20210812_lab.xml</File>
    <File>plx-20210812_pre.xml</File>
    <File>plx-20210812xex10d1.htm</File>
    <File>plx-20210812xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20210812x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20210812x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210812_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210812_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210812.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20210812",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210812x8k.htm",
      "contextRef": "Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210812x8k.htm",
      "contextRef": "Duration_8_12_2021_To_8_12_2021_2bD-QarVDk-3aIRjMxqoKQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20210812",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-21-011566-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-011566-xbrl.zip
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M(4VOLB!Z[JQ[041%*Y.:YX;I0Z5>%/>D9!73"I*(DF*+G=!=1#[X]QBD?8Y
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MOQJ^Z1"GH;B+_"F_KE@X;K^'XU!U*ZR0&$RI+M#R?%YH-Y1";9F'4I>X !V
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MZC]3RTS59+H-L^E:F\@WDA15=X&3:+GJQ1?T!UYV^K/XR1RXW6[7CGL-.7L
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ML%UL-)[4()/3E%,Z4P?$/HJU@R*"0@/L>FP(5<%#,0:_1<80@H#7BV$>?M(
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M!#8 75_88GQB>?,<' U#0;F&P5'+8$G@9C<<XCC> K] \P)P/D%*7=!J[';
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MDMHZ!L-1X4QC.=/^$*?'U<=\1?RPR6D 1-VW4B&>@*Y(#3GD.OW%YKQEU6G
MJ+2SNE.WQ[A\&SOO8/!BB$F:U<))SKS4Q%J%H&X>M2[^4XT>/._B/UW\Y^<
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M:IZ1W.&/T72"YH.ON3S7F;@UC(1*W]),XV]+B(?3 M!^2<<<@C2M1CE/,+9
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MVI[VXMASKK>="^P.F;1NX?/&%NYM[>_M;SW=?;:UO__\J;V%WH2>\U]C'.\
MAVNVKV,7=K);.&Q&ZEV'"F,SP[FQFY$)"TE.KDG*<M :;.'GB+[=% (>HW43
M0G8.<Z$;\5\0G$,03F$V*K,+2H1]+6D[L()V76HY).S7TB"UEV7%,BV,"(^
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M)JG/UD:%+5,JQ<#+&,H4?QY[5 X)<H!L)!1_;( T]3WWH0H?23<RF ?4^KT
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M\G;3%68YTH9.Z<*!%-44DN;C\-"(VD'E*A2CN TOP4W].0*I#G=D58A79 2
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MKOMU:_S[VY[\/U!+ 0(4 Q0    ( *DX#5--&-R,GP,  ) ,   0
M      "  0    !P;'@M,C R,3 X,3(N>'-D4$L! A0#%     @ J3@-4V_#
MP4JH!0  <3\  !0              ( !S0,  '!L>"TR,#(Q,#@Q,E]L86(N
M>&UL4$L! A0#%     @ J3@-4]?LJ"R6!   TBH  !0              ( !
MIPD  '!L>"TR,#(Q,#@Q,E]P<F4N>&UL4$L! A0#%     @ J3@-4X?SS;7X
M&@  A;L  !,              ( !;PX  '!L>"TR,#(Q,#@Q,G@X:RYH=&U0
M2P$"% ,4    " "I. U35>N=VME%   O& ( %P              @ &8*0
M<&QX+3(P,C$P.#$R>&5X,3!D,2YH=&U02P$"% ,4    " "I. U3HRU0[)H5
M  "33@  %P              @ &F;P  <&QX+3(P,C$P.#$R>&5X.3ED,2YH
8=&U02P4&      8 !@"- 0  =84

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
